10-Jul-2026
Q2 watchlist: Healthcare stocks with perfect EPS revision scores
Seeking Alpha News (Fri, 10-Jul 10:52 AM ET)
Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)
Globe Newswire (Fri, 26-Jun 4:01 PM ET)
Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Globe Newswire (Wed, 3-Jun 8:30 AM ET)
Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI's Image of the Year
Globe Newswire (Tue, 2-Jun 8:00 AM ET)
Lantheus to Present at the William Blair 46th Annual Growth Stock Conference
Globe Newswire (Wed, 27-May 8:30 AM ET)
Lantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting
Globe Newswire (Thu, 21-May 8:30 AM ET)
Globe Newswire (Tue, 19-May 8:30 AM ET)
Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 7-May 7:00 AM ET)
Globe Newswire (Thu, 23-Apr 8:00 AM ET)
Lantheus Narrows Focus on Radiodiagnostics After Reporting $1.54 Billion in 2025 Revenue
Market Chameleon (Thu, 26-Feb 3:36 AM ET)
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
Lantheus Holdings trades on the NASDAQ stock market under the symbol LNTH.
As of July 10, 2026, LNTH stock price declined to $105.64 with 908,566 million shares trading.
LNTH has a beta of 0.19, meaning it tends to be less sensitive to market movements. LNTH has a correlation of 0.00 to the broad based SPY ETF.
LNTH has a market cap of $6.88 billion. This is considered a Mid Cap stock.
Last quarter Lantheus Holdings reported $377 million in Revenue and $1.46 earnings per share. This beat revenue expectation by $22 million and exceeded earnings estimates by $.27.
In the last 3 years, LNTH traded as high as $126.89 and as low as $47.25.
The top ETF exchange traded funds that LNTH belongs to (by Net Assets): AVUV, IJH, VTI, IWM, VB.
LNTH has outperformed the market in the last year with a return of +26.0%, while the SPY ETF gained +21.8%. In the last 3 month period, LNTH beat the market returning +31.1%, while SPY returned +11.4%. However, in the most recent 2 weeks LNTH has underperformed the stock market by returning -3.8%, while SPY returned +3.6%.
LNTH support price is $103.32 and resistance is $108.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LNTH shares will trade within this expected range on the day.